A pilot study using proximity extension assay of cerebrospinal fluid and its extracellular vesicles identifies novel amyotrophic lateral sclerosis biomarker candidates
- PMID: 35567903
- DOI: 10.1016/j.bbrc.2022.04.127
A pilot study using proximity extension assay of cerebrospinal fluid and its extracellular vesicles identifies novel amyotrophic lateral sclerosis biomarker candidates
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder which is characterized by progressive degeneration of the motor system. Typically, the disease starts with focal weakness which spreads to involve most muscles and leads to death from respiratory failure within five years of diagnosis. Due to the heterogenic nature of the disease, diagnostics is complex, and it generally takes twelve months from symptom-onset to diagnosis. The discovery of novel biomarkers could lead to accelerated diagnosis, earlier start of treatment, improved patient-segmentation, and treatment follow-up as well as an increased insight into the pathology. Here, we analyzed cerebrospinal fluid (CSF) and CSF-derived extracellular vesicles (CSF-EVs) from ALS-patients and matched controls (n = 9 each) using the ultra-sensitive proximity extension assay (PEA), cardiovascular III-panel. On average, 84 and 61 proteins could be detected in CSF and CSF-EVs respectively. In CSF, three proteins were significantly upregulated in ALS-patients (Junctional Adhesion Molecule A Protein, Tumor necrosis factor receptor 2 and Chitinase 1) while myoglobin was down-regulated. In CSF-EVs, no significantly differentially expressed proteins were identified, but there was a trend for downregulation of Perlecan. To our knowledge, only CHIT1 has been previously described as a CSF-based biomarker candidate for ALS. By combining the four differentially expressed markers in CSF and support vector machine algorithm, all ALS patients and 8 of 9 controls were correctly classified. In conclusion, we here demonstrate the feasibility of using PEA of CSF and CSF-EVs for biomarker discovery and propose three de novo biomarker candidates for ALS, however, further studies are necessary to demonstrate clinical usability.
Keywords: Amyotrophic lateral sclerosis; Cerebrospinal fluid; Extracellular vesicles; Proximity extension assay.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest S.S. and K.O. are employees of Takeda Pharmaceutical Company Limited. S.S. is co-founder and co-owner of ExTherea Limited. S.S. is a minor shareholder of Takeda Pharmaceutical Company Limited and Olink Proteomics AB. K.O. is a minor shareholder of Takeda Pharmaceutical Company Limited.
Similar articles
-
Extracellular Vesicles as Potential Biomarkers in Amyotrophic Lateral Sclerosis.Genes (Basel). 2023 Jan 27;14(2):325. doi: 10.3390/genes14020325. Genes (Basel). 2023. PMID: 36833252 Free PMC article. Review.
-
Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.J Proteome Res. 2015 Nov 6;14(11):4486-501. doi: 10.1021/acs.jproteome.5b00804. Epub 2015 Oct 8. J Proteome Res. 2015. PMID: 26401960 Free PMC article.
-
Saliva and Saliva Extracellular Vesicles for Biomarker Candidate Identification-Assay Development and Pilot Study in Amyotrophic Lateral Sclerosis.Int J Mol Sci. 2023 Mar 9;24(6):5237. doi: 10.3390/ijms24065237. Int J Mol Sci. 2023. PMID: 36982312 Free PMC article.
-
Analysis of Cerebrospinal Fluid Extracellular Vesicles by Proximity Extension Assay: A Comparative Study of Four Isolation Kits.Int J Mol Sci. 2020 Dec 10;21(24):9425. doi: 10.3390/ijms21249425. Int J Mol Sci. 2020. PMID: 33321992 Free PMC article.
-
Extracellular vesicles and amyotrophic lateral sclerosis: from misfolded protein vehicles to promising clinical biomarkers.Cell Mol Life Sci. 2021 Jan;78(2):561-572. doi: 10.1007/s00018-020-03619-3. Epub 2020 Aug 16. Cell Mol Life Sci. 2021. PMID: 32803397 Free PMC article. Review.
Cited by
-
Extracellular Vesicles as Potential Biomarkers in Amyotrophic Lateral Sclerosis.Genes (Basel). 2023 Jan 27;14(2):325. doi: 10.3390/genes14020325. Genes (Basel). 2023. PMID: 36833252 Free PMC article. Review.
-
Extracellular vesicles in TDP-43 proteinopathies: pathogenesis and biomarker potential.Mol Neurodegener. 2025 Jun 10;20(1):68. doi: 10.1186/s13024-025-00859-4. Mol Neurodegener. 2025. PMID: 40495245 Free PMC article. Review.
-
Combinational treatments of RNA interference and extracellular vesicles in the spinocerebellar ataxia.Front Mol Neurosci. 2022 Oct 13;15:1043947. doi: 10.3389/fnmol.2022.1043947. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36311034 Free PMC article. Review.
-
Central nervous system-derived extracellular vesicles: the next generation of neural circulating biomarkers?Transl Neurodegener. 2024 Jun 19;13(1):32. doi: 10.1186/s40035-024-00418-9. Transl Neurodegener. 2024. PMID: 38898538 Free PMC article. Review.
-
Liquid Biopsy in Neurological Diseases.Cells. 2023 Jul 22;12(14):1911. doi: 10.3390/cells12141911. Cells. 2023. PMID: 37508574 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous